Table 3.
All stages | T1 | T2 | T3 | T4 | |
---|---|---|---|---|---|
Multivariable a HR (95% CI) |
Multivariable b HR (95% CI) |
Multivariable b HR (95% CI) |
Multivariable b HR (95% CI) |
Multivariable b HR (95% CI) |
|
LND status | |||||
No LND | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) |
LND | 0.87 (0.80–0.95)** | 0.98 (0.80–1.19) | 0.85 (0.70–1.04) | 0.88 (0.78–0.99)* | 0.74 (0.59–0.94)* |
LND extent | |||||
No LND | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) |
Limited LND | 0.90 (0.81–0.99)* | 0.98 (0.78–1.25) | 0.87 (0.69–1.11) | 0.93 (0.81–1.07) | 0.73 (0.57–0.94)** |
Extended LND | 0.83 (0.74–0.94)** | 0.97 (0.73–1.30) | 0.82 (0.61–1.09) | 0.80 (0.68–0.95)* | 0.77 (0.57–0.99)* |
Lymph node stage | |||||
pN0 | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) |
pNx | 1.19 (1.08–1.30)*** | 1.05 (0.86–1.29) | 1.20 (0.98–1.48) | 1.15 (1.01–1.31)* | 1.59 (1.20–2.11)** |
pN1–3 | 2.20 (1.93–2.50)*** | 2.13 (1.33–3.41)** | 2.33 (1.60–3.40)*** | 2.00 (1.68–2.39)*** | 2.26 (1.65–3.10)*** |
*P < 0.05, **P < 0.01, ***P < 0.001. a Adjusted to age, gender, race, tumor location, laterality, tumor size, tumor stage, tumor grade, chemotherapy and year of surgery. b Adjusted to age, gender, race, tumor location, laterality, tumor size, tumor grade, chemotherapy and year of surgery. HR hazard ratio, 95% CI 95% confidence interval, LND lymph node dissection